| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| Targets |
Human Endogenous Metabolite ERK MEK
|
|---|---|
| ln Vitro |
C16-PAF (PAF (C16); 0.5-1.5 μM; for 24 hours) triggers considerable concentration-dependent neuronal death in PAFR?/? but not PAFR+/+ cultures. C16-PAF (1 μM) triggers neuronal death in PAFR? /? cells infected with EGFP alone[1]. ?C16-PAF (1 μM; for 24 hours) activates caspase 7 but not caspase 3 in PAFR?/? neurons[1]. ?C16-PAF is generated by two separate processes ; the remodeling pathway and the de novo synthesis pathway. C16-PAF functions by interacting to a unique G-protein-coupled seven transmembrane receptor[2][3]. ?C16-PAF (1-25 μg/ml; 6, 12 , 24 h) inhibits M. smegmatis and M. bovis BCG growth in a time-dependent manner[3].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: Cerebellar granule neurons (CGNs) from PAFR−/− and PAFR+/+ mice Tested Concentrations: 0.5-1.5 μM Incubation Duration: 24 hrs (hours) Experimental Results: Elicited significant concentration-dependent neuronal loss in PAFR−/− but not PAFR+/+ cultures in serum-free media. Western Blot Analysis[1] Cell Types: CGNs Tested Concentrations: 1 μM Incubation Duration: 24 hrs (hours) Experimental Results: Activated caspase 7 but not caspase 3 in PAFR−/− neurons. |
| References |
|
| Additional Infomation |
2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine is a 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine betaine which has hexadecyl as the alkyl group. PAF is a potent phospholipid activator and mediator of many leukocyte functions, including platelet aggregation, inflammation, and anaphylaxis. It has a role as a beta-adrenergic antagonist, an antihypertensive agent, a bronchoconstrictor agent, a hematologic agent and a vasodilator agent.
Platelet Activating Factor is a phosphatidylcholine derivative that modulates inflammation, vascular permeability, allergic responses and the functions of leukocytes and platelets. A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION. |
| Molecular Formula |
C26H54NO7P
|
|---|---|
| Molecular Weight |
523.68
|
| Exact Mass |
523.363
|
| CAS # |
74389-68-7
|
| PubChem CID |
108156
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.94
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
26
|
| Heavy Atom Count |
35
|
| Complexity |
546
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCCCCCCCCCCCCCOC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)C
|
| InChi Key |
HVAUUPRFYPCOCA-AREMUKBSSA-N
|
| InChi Code |
InChI=1S/C26H54NO7P/c1-6-7-8-9-10-11-12-13-14-15-16-17-18-19-21-31-23-26(34-25(2)28)24-33-35(29,30)32-22-20-27(3,4)5/h26H,6-24H2,1-5H3/t26-/m1/s1
|
| Chemical Name |
[(2R)-2-acetyloxy-3-hexadecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (95.48 mM)
H2O: 33.33 mg/mL (63.65 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (4.77 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.77 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9096 mL | 9.5478 mL | 19.0956 mL | |
| 5 mM | 0.3819 mL | 1.9096 mL | 3.8191 mL | |
| 10 mM | 0.1910 mL | 0.9548 mL | 1.9096 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
